Steroid treatment: the long and the short of it

Article

A study published in the March issue of Acta Ophthalmologica Scandinavica, has found that long-term treatment with a topical steroid after penetrating keratoplasty (PK) is no better at preserving endothelial cell density than short-term treatment.

A study published in the March issue of Acta Ophthalmologica Scandinavica, has found that long-term treatment with a topical steroid after penetrating keratoplasty (PK) is no better at preserving endothelial cell density than short-term treatment.

Nhung Xuan Nguyen and colleagues from the University of Erlangen-Nürnberg, Germany, compared the effects of long- and short-term topical steroid use on endothelial cell counts in 305 subjects. All patients, after undergoing PK, received prednisolone acetate 1% eye drops five times a day. This was slowly tapered over a six-month period. Patients were randomly assigned to the short-term group, which ceased steroid treatment, or the long-term group, which continued with the treatment once daily for a further 12 months.

A significant postoperative decrease in endothelial cell density was observed in both groups. At six-week follow-up, cell densities averaged 1,941 cells/mm2 in the short-term group and 1,957 cells/mm2 in the long-term group. At two-year follow-up, cell density had decreased significantly to 1,535 cells/mm2 and 1,472 cells/mm2, respectively (p<0.001).

Using linear regression, the researchers calculated that subjects in the short-term group lost an average of 216 cells/mm2 per year, while those in the long-term group lost an average of 206 cells/mm2 (p=0.5).

Analysis of the results revealed that there is no significant difference in cell density between patients on long- and short-term steroid treatment following penetrating keratoplasty.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.